News & Updates
Filter by Specialty:
Fezolinetant reduces menopause-related vasomotor symptoms
Treatment with fezolinetant 30 and 45 mg daily provides relief from moderate-to-severe vasomotor symptoms (VSM) associated with menopause, suggests a study.
Fezolinetant reduces menopause-related vasomotor symptoms
18 Aug 2023
Long-term hydrochlorothiazide use ups risk of skin cancer
Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.
Long-term hydrochlorothiazide use ups risk of skin cancer
17 Aug 2023
Demedicalized delivery of PrEP possible, improves access
A peer-led demedicalized delivery of same-day HIV pre-exposure prophylaxis (PrEP) in various community centres is feasible, suggests a Philippines study presented at the recent IAS 2023.
Demedicalized delivery of PrEP possible, improves access
16 Aug 2023
Meeting gender-affirming needs tied to accessing HIV services among transgender people
Having met gender-affirming care needs among transgender people is associated with accessing HIV-related services in a community-led clinic, as shown in a Philippines study presented at IAS 2023.
Meeting gender-affirming needs tied to accessing HIV services among transgender people
16 Aug 2023
Dapagliflozin cuts risk of total HF events, CV deaths in HF patients
In a prespecified analysis of the DELIVER* study, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the rate of total** heart failure (HF) events or cardiovascular (CV) deaths in HF patients with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF).